Last reviewed · How we verify

NCT05297019: HBOT

A Dosing Study of Hyperbaric Oxygen Therapy (HBOT) on Epigenetic Aging

Status unknown Phase 2, PHASE3 Last updated 12 April 2023
What this trial tests

Phase 2, PHASE3 trial testing Hyperbaric Oxygen Therapy in Aging in 30 participants. Status unknown.

Timeline
1 March 2022
Primary endpoint
30 April 2023
1 July 2023

Quick facts

Lead sponsorTruDiagnostic
PhasePhase 2, PHASE3
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingtriple
Primary purposehealth services research
Enrollment30
Start date1 March 2022
Primary completion30 April 2023
Estimated completion1 July 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

TruDiagnostic — full company profile →

Who can join

Adults 40 to 70, any sex, with Aging. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to assess the impact of hyperbaric oxygen therapy on a number of outcomes, including epigenetic aging, inflammation, and cellular health.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Hyperbaric Oxygen Therapy

Trials testing the same drug.

Other recruiting trials for Aging

Currently open trials in the same condition.

Other TruDiagnostic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05297019.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing